drugset / Trial / NCT01506908

Provoked Craving Assessment

NCT01506908

Phase 2 Completed 323 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of the ability of a nicotine mini lozenge to provide early relief of craving for a cigarette in smokers

Timeline

Start
2011-09
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicotine Unknown 1.5 mg Oral
Comparator Nicotine Unknown 4 mg Oral

Indications